Kenvue's Extra-Strength Migraine Just Came Back From the Dead (500 times…)

RFK Jr. just went from six to midnight.

There are headaches Tylenol can fix, and then there's the one a federal appeals court just handed the company that makes it. On Monday, the 2nd U.S. Circuit Court of Appeals brought a sh*tload of lawsuits (500-plus, officially) against Kenvue back from the dead… cases mainly from parents alleging that Tylenol use during pregnancy caused their children's autism or ADHD. Kenvue stock slipped about 2%, which doesn’t sound too bad until you remember the entire company is supposed to be somebody else’s baggage by Christmas. 

And yet, this is a BFD because these cases were already dead. U.S. District Judge Denise Cote dismissed the whole pile in December 2024 after deciding the parents' three expert witnesses (Andrea Baccarelli, the dean of Harvard's School of Public Health, plus a Columbia toxicologist and an Einstein psychiatry professor) were using methodology too shaky for a courtroom, and benched all three. The 2nd Circuit went to the monitor and waved them right back onto the pitch. In a unanimous 64-page decision, Judge Guido Calabresi wrote that the doctors' methods are ones real scientists actually use, "acceptable interpretations of scientific evidence where scientists may, and in fact do, disagree."

Translation: Nobody ruled that Tylenol makes you like trains a little more than usual. And there is STILL no firm scientific evidence of a link. In fact, a 700,000-family study out of Hong Kong found no connection just last week, and doctors still consider acetaminophen THE pain-and-fever option during pregnancy. Monday's ruling is about who gets to talk, not who's right: you can't toss the experts before a jury ever hears them. So all 500 cases now boomerang back to Judge Cote's courtroom. Pour one out for the jury on this one. 

Oh, and Kenvue isn't the only one lawyered up. CVS, Kroger, Target, Walgreens, and Walmart are all named too, because every store-brand acetaminophen bottle in America just became a co-defendant. Johnson & Johnson, which made Tylenol for 60 years before spinning Kenvue off in 2023, is watching from a safe distance. (The spinoff ages better every quarter.)

Of course, the worst seat in the house Monday didn't belong to Kenvue at all. The Kleenex people (read: Kimberly-Clark) agreed last November to buy the whole company for $48.7 billion, shareholders blessed it in January, and the deal is supposed to close in the back half of this year. That works out to roughly $97 million per freshly resurrected lawsuit. Kimberly-Clark stock fell 2.7%, worse than Kenvue itself, which is what happens when you're months away from wiring the money for 500 clusterf*cks. 

Meanwhile, in Washington, somebody's summer just got made. President Trump and top health officials spent last September urging pregnant women to limit Tylenol, and HHS Secretary RFK Jr. has since settled on the official position that the evidence is "not sufficient to say it definitely caused autism, but it is very suggestive." None of that is proof, but Kenvue’s lawyers aren’t sweating proof… they're sweating jury pools that have been marinating in this story for ten months. Expert testimony is the whole ballgame in cases like these, and that's exactly why Kenvue fought to keep it out the first time. "We stand behind the safety of our product," the company said Monday. (Read: see you in court. Five hundred times.)

So what do we do from here? Well watch two dates. The first being, how fast Judge Cote schedules round two, and whether Kimberly-Clark's "second half of 2026" close stays put now that the purchase comes with a bonus docket. Until then, place your bets accordingly, friends. See you next time… 

At the time of publishing, Stocks.News holds positions in Johnson & Johnson as mentioned in the article.